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1. Introduction 1	
 2	
Dengue fever is the fastest-spreading tropical and vector-borne viral disease worldwide 3	
(WHO, 2009). There is no specific treatment for it, although appropriate medical care 4	
frequently saves the lives of people suffering from severe forms (Cattand, 2006). It is 5	
estimated that about 3.97 billion individuals, 56% of the world population, inhabit areas 6	
where there is a risk of transmission of dengue fever (Brady et al., 2012). The World Health 7	
Organisation (WHO) estimates 22,000 deaths per year and case-fatality rates in adults and in 8	
children can be as high as 33% if fluid management is inadequate or delayed (Halstead and 9	
Deen, 2002). Similar to other infectious diseases, reported cases are a small fraction of 10	
estimated total cases (Bärnighausen et al., 2013). Moreover, in endemic regions, the probable 11	
dengue fever disease burden in disability-adjusted life years (DALYs) is high: 0.42 per 1,000 12	
population (Guzman and Isturiz, 2010), an increase in years lived with disability due to 13	
dengue has been observed, highlighting its steadily growing non-fatal burden of disease (Vos 14	
et al., 2015).  15	
The disease presents considerable economic and social disease burdens to middle and low-16	
income countries and over the past three decades there has been an increase in incidence rates 17	
with a concomitant increase of complications and severe cases. Furthermore, studies have 18	
shown that managing dengue illness requires multiple visits to health services, resulting in 19	
missed days of school and work, medical and non-medical expenditures, and foregone 20	
household productivity and income (Torres and Castro, 2007), (Suaya et al., 2009), (Shepard 21	
et al., 2013). 22	
Vector control programmes have been the main preventive measure adopted to prevent and 23	
control dengue fever throughout the years in endemic countries but they have proved to be 24	
largely ineffective to control dengue transmission or epidemics (Erlanger et al, 2008), 25	
(Horstick et al., 2010), (Stahl et al, 2013). Recently, the first dengue vaccine was licensed in 26	
Mexico and has been since licensed in several countries (Vannice et al., 2015). Reports and 27	
studies have shown an overall vaccine efficacy of 59.2  60.8% and a significant efficacy 28	
variation according to serotype, age and among those previously exposed to dengue fever 29	
(Villar et al., 2014). Other vaccine candidates are in an advanced stage of development, using 30	
a variety of technological approaches, and they represent a decisive opportunity to control the 31	
disease (Vannice et al., 2015), (Hadinegoro et al., 2015).  32	
The implementation of a new vaccine programme is often a costly process with long-term 33	
consequences and to gain a better understanding of the potential impact on health benefits 34	
and costs of a vaccine intervention, health economic studies are frequently used for 35	
estimating future impacts on health gains and costs (Bos, 2010), (Beutels et al., 2003). 36	
Studies about cost-effectiveness, fiscal impact and financial sustainability of new vaccines, 37	
for example, have guided implementation of national immunization programmes in some 38	
countries and specific guidelines have been published by the WHO to help improve the 39	
quality of economic studies evaluating vaccination programmes (WHO, 2008), (Tucker et al., 40	
1998).  41	
 42	
Developing countries are considerably affected by constraints on health care budgets and 43	
frequently face difficult decisions on the allocation of health resources. In this sense, the 44	
current trend in the public sector is to encourage transparent and evidence-based policy 45	
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decisions, in order to use resources effectively and efficiently. Consequently economic 46	
evaluation has acquired greater importance among decision-makers who have been pressured 47	
 (Andrus et al., 48	
2007), (UNICEF, 2009), (Tozan, 2016). 49	
 50	
The development of a safe and effective dengue vaccine is moving forward at an 51	
unprecedented rate, especially because of improvements related to reverse genetics, with a 52	
high likelihood that the challenges of vaccine development and implementation can be 53	
overcome very soon (Guy et al., 2011), (Hadinegoro et al., 2015).	 54	
As recent studies have shown safe and effective dengue fever vaccines are at final stages of 55	
development and licensing is already a reality, it is essential to carefully analyze its potential 56	
economic impacts (Halstead and Deen, 2002), (Whitehead et al., 2007), (Guy et al., 2011), 57	
(WHO, 2012) to aid forthcoming resource allocation decisions for budget holders (Tozan, 58	
2016). We do so by reviewing the available evidence to date. We also take the opportunity to 59	
compare findings from three separate checklists for assessing the quality of economic 60	
evaluation evidence. 61	
2. Methods 62	
Search strategy and selection criteria 63	
A multi-stage process was designed and undertaken to systematically select relevant 64	
publications, based on PRISMA guidelines (Moher et al., 2009). The electronic literature 65	
search was performed in six electronic databases: PubMed/MEDLINE, EMBASE, Web of 66	
Science, Global Health, Latin American and Caribbean Health Sciences Literature (LILACS) 67	
and NHS Economic Evaluation Database (NHS EED). Searches were restricted to papers 68	
published between January 1970 and February 2016 and written in English, Spanish or 69	
Portuguese. Search terms, including MeSH descriptors and free text terms, were divided into 70	
three categories: dengue fever, vaccine, and economic evidence. Search terms and results are 71	
detailed in appendices 1 and 2.   72	
 73	
Three reviewers (IE, PZ, AP) performed an eligibility assessment on the initially retrieved 74	
results, unblinded and independently. Titles, abstracts and key words were screened to 75	
determine whether they fulfilled the inclusion criteria: 1) included economic evidence 76	
focused on dengue fever vaccine; 2) involved original data analysis; and 3) written in 77	
English, Spanish or Portuguese. Editorials, letters to editors, opinion papers, meeting reports 78	
and conference reports were excluded. After the screening process was concluded, the full 79	
texts of selected abstracts were obtained to check their fulfillment of the inclusion criteria. As 80	
a final stage to the publication selection, we hand-searched reference lists of each of the 81	
papers selected for inclusion based on the electronic search to ensure that we had not missed 82	
any key publications. See Figure 1 for the complete study selection process. 83	
Data extraction and quality assessment 84	
Data extraction was designed to systematically summarize key elements from selected studies 85	
(Table 1), focusing on providing sufficient detail to allow comparison and was based on two 86	
published studies (Constenla et al., 2015), (Beatty et al., 2011). 87	
 88	
Selected publications were critically appraised by three reviewers independently using three 89	
publicly available checklists:  (Drummond and Jefferson, 90	
1996), (Appendix 3); for appraising the quality of economic 91	
evaluations of immunization programmes (WHO 2008), (Appendix 4); and the nla et 92	
(Constenla et al, 2015), (Appendix 5). Although the three checklists share many 93	
similarities, they contain some exclusive items, categorise items differently and recommend 94	
different methodologies to grade the overall quality assessment results.  95	
With regards to categorization of items, (Constenla et al, 96	
2015) divides 17 questions into three categories: study design, data collection, analysis and 97	
interpretation. It is important to note that although it is mentioned the quality checklist 98	
contains 19 questions, only 17 questions are presented in appendix 2 in Constenla et al., 2015 99	
and questions 13 and 14 are absent. 100	
(Drummond and Jefferson, 1996) are also 101	
categorized this way. The s 28 questions into 102	
eight sections: framing, costs, effects, modelling, discounting, uncertainty, other factors and 103	
conclusions. To recognize similarities among the checklists and to facilitate comparisons 104	
across categories, reviewers  and items 15 and 16 from 105	
y   corresponded to 106	107	
corresponded  (Table 3 and Appendix 4). 108	
In terms of grading, 109	
according to importance. The other two checklists lack such a mechanism so, for those two, 110	111	
app112	113	
per category. 114	
3. Results 115	
 116	
The electronic searches yielded 1,098 articles after removal of duplicates, of which 27 studies 117	
met the inclusion criteria on the basis of their title and abstract. These papers were then 118	
assessed in full-text, and 18 were further removed, mainly because they were not an original 119	
analysis or did not focus on dengue fever vaccine economic evidence. This resulted in only 120	
nine studies satisfying the eligibility criteria. Two further studies were identified after manual 121	
review, resulting in 11 studies, all of which were written in English, meeting the inclusion 122	
criteria for the final qualitative and quantitative analysis (Table 1).  123	
 124	
Most studies were based on data from countries in south-east Asia, although 6 studies also 125	
presented results from America regions. There were four multi-country papers and three 126	
studies focusing on cost-effectiveness of a dengue fever vaccine were performed by the same 127	
main author (Shepard), in what can be described as a series of analyses throughout the years 128	
(1993, 2004 and 2010). It is also important to note that most included studies also referred to 129	
initial studies from this author. 130	
 131	
The perspective of society was used in most cases and one study also discussed the 132	
manufacturer perspective (Mahoney et al., 2012). The time horizon used in all studies but one 133	
(Mahoney et al., 2012) was based on life expectancy.  134	
 135	
Types of study designs varied across studies and cost-effectiveness analysis dominated as the 136	
methodological approach performed most frequently. Three studies (Palanca-Tan, 2008), 137	
(Hadisoemarto and Castro, 2013), (Lee et al., 2015) are willingness to pay for dengue vaccine 138	
analyses and can be classified as partial economic evaluations since they provide less detailed 139	
information relating to description, measurement or valuation of resources associated with 140	
dengue fever vaccines. One study was a cost-description about the feasibility of producing 141	
dengue vaccines (Mahoney et al., 2012).  142	
Secondary data sources were used in all economic evaluation studies and were frequently 143	
derived from published literature and surveillance reports. Primary data collection was 144	
undertaken in the three willingness to pay for dengue vaccine studies. Recent studies 145	
generally compared interventions like clinical management and vector control programmes 146	
with vaccination. A total of five studies analysed less complex scenarios comparing 147	
vaccination and absence of specific immunization programmes.  148	
Most studies used some kind of economic modelling; however, no studies provided 149	
justification for the selection of a particular type of model or its key parameters. A decision 150	
tree /model was included as a figure in 4 studies (Shepard et al., 2004), (Shepard et al., 2010, 151	
(Lee at al., 2011), (Orellano et al., 2015). Similarly, discount rates were often stated, but 152	
without justification for the choice of a specific rate. Details of statistical tests and confidence 153	
intervals used in the studies were not frequently stated and only four studies (Palanca-Tan, 154	
2008), (Durham et al., 2013), (Lee et al., 2015), (Hadisoemarto and Castro, 2013) made 155	
reference to this. 156	
 157	
The majority of studies used and referenced cost estimates from previous studies rather than 158	
re-estimating new costs; there was considerable variation in cost measures and most relevant 159	
costs were not recent as only three studies (Mahoney et al., 2012), (Orellano et al., 2015), 160	
(Durham et al., 2013) used data from within 2-3 years prior to the study being published. 161	
Included are direct costs for medical care and vector control measures and indirect costs for 162	
lost production due to illness and absenteeism by patients and by parents caring for sick 163	
children. Indirect costs were measured and reported separately from direct cost only in two 164	
studies (Carrasco et al., 2011), (Orellano et al., 2015). 165	
 166	
Most studies did not consider productivity changes, two studies (Carrasco et al. 2011), (Lee 167	
et al., 2011) made reference to productivity losses in its analysis, but without further 168	
discussion or specific reporting on this aspect of the analysis.  169	
Details on price adjustments for inflation or currency conversion were neglected; four studies 170	
(Shepard, 1993), (Mahoney et al., 2012), (Durham et al., 2013), (Orellano et al., 2015)  did 171	
not make reference to any such detail, and three others (Carrasco et al. 2011), (Palanca-Tan, 172	
2008), (Shepard et al., 2004) only accounted for one item at a time (e.g. conversion but not 173	
inflation).  174	
 175	
All included studies based their analysis on assumptions related to future or recent prospects 176	
of dengue fever vaccines derived from current scientific literature, including details about 177	
how vaccine prices where estimated, with the exception of two studies (Mahoney et al. 2012), 178	
(Lee at al., 2015). However, details of methods of synthesis or meta-analysis of dengue fever 179	
vaccines estimates were not provided by most of reviewed studies. All studies considered 180	
vaccine efficacy and coverage. Three studies varied the vaccine dose regime scenario and 181	
there was a wide variation in prices per dose among studies reviewed. 182	
 183	
Sensitivity analysis was described by seven studies; however, only three studies (Shepard et 184	
al., 2004), (Shepard, 2010), (Durham et al., 2013) justified their choice of variables, while 185	
one study did not state the range over which sensitivity parameters were varied (Mahoney et 186	
al. 2012).  187	
 188	
Detailed reports on incremental analysis were not a frequent finding. However, in six studies 189	
(Shepard, 1993), (Carrasco et al., 2011), (Lee et al. 2011), (Durham et al., 2013), (Lee et al., 190	
2015), (Orellano et al., 2015) it was possible to find brief details of such an approach. 191	
Remarks on generalisability issues were another rare finding and were clearly addressed in 192	
only two studies (Carrasco et al. 2011), (Shepard, 2010). A193	
considered to be ungeneralizable due to limited data about the vaccine and regional 194	
characteristics associated with study design and methodology. 195	
 196	
Out of the six studies that expressed disability-adjusted life years (DALYs) as an outcome 197	
measure to evaluate economic impact or cost-effectiveness of dengue vaccines, two presented 198	
the incremental cost-effectiveness ratio in units of cost per DALY averted (Lee et al. 2011), 199	
(Orellano et al., 2015). 200	
The results of most studies showed that the dengue vaccine could be of considerable 201	
economic value but results were conditionally linked with vaccine prices, vaccine efficacy, 202	
coverage vaccine regime (number of doses) and strategy. In some cases, vaccination could 203	
provide net cost savings. All studies presented analyses linking costs to outcomes but only 204	
one recent study (Orellano et al., 2015) clearly used cost-effectiveness thresholds for the 205	
analysis. 206	
Potential sources of bias were not clearly stated by four studies (Shepard et al., 1993), 207	
(Palanca-Tan, 2008), (Durham et al., 2013), (Lee at al., 2015) and comparisons were made 208	
with other studies in all included papers but they were only partial in 6 studies. 209	
 210	
All studies but one (Shepard et al., 2010) have clearly acknowledged their funding sources 211	
and authors have declared there was no conflict of interest related to financial support or 212	
authors´ affiliations. Non-profit organisations (government agency, non-profit foundation, or 213	
academic institution) were responsible for financial support in ten of eleven included articles. 214	
Evaluating quality of evidence 215	
Although the overall quality of included studies was considered to be satisfactory as averages 216	
for positive answers according to each of the checklists were greater than 59%, some specific 217	
methodological issues still need more attention, especially in relation to data collection and 218	
analysis and interpretation. The standard deviations show that the papers were similar in 219	
terms of their quality, with few outliers (Table 2, Table 3 and Table 4). 220	
Furthermore, despite the different methods for scoring applied for the three checklists, as 221	
there was no penalty for partially positive answers on  and 222	
assessments, the overall scores showed a similar pattern when compared to 223	
percentage of positive answers. The  overall score was the lowest as the 224	
average was 13 (59  average score was 23.09 225	
(73%) and the  25.05 (66.7%)  226	
Quality assessment based on the Drummond/BMJ checklist  (Drummond and Jefferson, 227	
1996) revealed that on average 89.6% questions were considered applicable to selected 228	
studies, 73% responses were positive, 4.7% were considered as partial and 22.2% of the 229	
answers were negative. According to this checklist,  the area in most need forimprovement is 230	
data collection, scoring an average of 7.45 (62.6 %) (Table 2). 231	
Comparatively, quality assessment using the WHO checklist  revealed a lower percentage 232	
of positive answers among studies (Table 3). On average, 78.5% of questions were applicable 233	
to the included studies, 59% responses were positive, 13% were marked as partial and 27.6% 234	
were negative answers. Checklist scores suggested that the areas needing improvement 235	
related to data collection, and one section (discounting) associated with analysis and 236	
interpertation of results was evaluated as the lowest percentage for the overall checklist rating 237	
by category (Table 3). 238	
 (Table 4) required the use of 239	
a different method for scoring, but shared a higher degree of similarity, for question content 240	
and categories, with the  rather than with the 241	
Papers on average scored 25.05 (66.7%) out of 37.5 possible points and the area in most need 242	
for improvement was data collection, scoring 6.27 (46.4%) out of 13.5.  243	
In terms of ranking the results of quality assessment, two studies (Palanca-Tan, 2008), (Lee at 244	
al., 2015) were evaluated as the lowest quality for all checklists. Moreover, the three studies 245	
associated with less quality according to the 246	
 were the same, and the study ranked as of the least quality (Mahoney et al., 2012) 247	
was not among the lower scores based on  248	
On the other hand, ranking studies according to scores for the highest quality did not show 249	
any matching results among the three checklists, although one study (Durham et al., 2013) 250	
reached a higher percentage of positive responses for the 251	
the one of the three best 252	
evaluated using the also the  253	
 254	
4. Discussion 255	
 256	
This review indicates that economic analyses of future prospects for dengue fever vaccines 257	
are few in number and, although reviewed studies display different baseline assumptions and 258	
modelling designs, relevant methodological approaches were taken and findings were similar.  259	
 260	
Studies to date, based on economic modelling approaches, make a clear case for vaccines 261	
potentially having a substantial impact on the epidemiology of this disease, even though 262	
assumptions about vaccination programmes may vary substantially. Although analysis 263	
adjustments may be necessary as critical information may be different in the future, cost-264	
effectiveness analysis can play an important role in the decision-making process of 265	
implementing dengue fever vaccines as it allows comparison between health burdens and 266	
health gains provided by different measures of prevention and control (Siqueira Jr et al., 267	
2005), (Halstead, 2012).  268	
 269	
Results indicate that economic analyses have been performed by a restricted number of 270	
authors and in few countries when considering the potentially dengue fever affected areas in 271	
the world. While this facilitates comparison and interpretation among studies, there is a risk 272	
of bias as authors  preconceptions may affect interpretation of results, interfere with a 273	
 (Kimman et al., 2006). 274	
 275	
Although quality assessment of economic evaluations is a relatively new approach for 276	
vaccination programmes and there are no generally accepted criteria for reviewing economic 277	
evidence (Higgins et al., 2008), the overall quality of studies was considered to be 278	
satisfactory. Further, results of critical appraisal did not show considerable differences in 279	
quality levels between three quality assessment checklists, with overall quality scores  being 280	
similar across checklists.  281	
It is important to highlight, however, there is some variability among the checklists which 282	
may be related to each s design and specific purpose. For some included studies, 283	
lower scores 284	
aims to assess the quality of economic evaluations of immunization programmes, while the 285	
two other checklists aim to assess general economic evaluations.  286	
Another explanation for some differences in quality assessment results is differences in the 287	
formulation of questions. Responses for  ere appropriate comparisons made with other 288	
studies? , for example, were generally positive. On the other hand, answers for the more 289	
specific question of ave the findings been compared to other economic evaluations 290	
undertaken in the same or neighbouring countries?  usually negative. 291	
Although there is no consensus on whether guidelines improve the quality of the economic 292	
evaluations, studies should focus on transparency of reporting, which can be aided by the use 293	
of validated quality assessment checklists (Drummond and Jefferson, 1996). On the other 294	
hand, validity of an economic evaluation may be difficult to assess due to limitations in 295	
reporting and some authors advise it is preferable to present a checklist describing methods, 296	
results, strengths, weaknesses and the implications on their conclusions (Husereau et al., 297	
2013). Our use and comparison of three recognized checklists has shown that the quality of 298	
reporting of economic evaluations may vary and could be potentially improved as a quality 299	
assurance mechanism (Husereau et al., 2013). However, it is important to highlight that 300	
quality assessment by checklists does not distinguish between major flaws and simple 301	
weaknesses, and simplistic interpretation of results may be misleading (Bos, 2010). 302	303	
 304	
The way results of economic evaluations are reported and interpreted is extremely important. 305	
Data are inevitably specific to a context and may be subject to reinterpretation if vaccine 306	
features change considerably from what is expected at the present time. The emphasis in the 307	
reporting should reside on transparency since without a clear display of parameters used in 308	
modelling, it is hard to determine if an economic model provides an accurate description of 309	
epidemiological patterns expected prior to a vaccination programme and, therefore, if they 310	
can be used to predict future incidence and outcomes associated with introducing the vaccine 311	
(Drummond and Jefferson, 1996). 312	
Furthermore, using uncertainty analysis throughout the process of reviewing one or more 313	
parameters will help to identify those that will have a greater impact on the results. In a 314	
scenario where the price per dose is uncertain, for instance, a threshold analysis may be less 315	
susceptible to drastic changes on results and interpretation (Tucker et al., 1998). 316	
Relevant aspects of vaccine pricing and the total cost of vaccination per fully immunized 317	
person are important variables, expected to vary across countries according to the way costs 318	
are estimated, and affecting the cost-effectiveness analysis results (Brenzel et al, 2006). To 319	
enable evidence-based decision making, country-specific costing studies should provide 320	
updated detailed data to enable analysis where it is possible to vary key inputs, such as the 321	
mix of vaccine delivery strategies and the scale of vaccination programmes (Tozan, 2016).  322	
Considering several promising vaccine candidates are currently in the later stages of clinical 323	
development, and the first dengue vaccine was recently licensed, it is necessary to continue 324	
dengue surveillance to ensure evaluations of vaccine performance and immunization 325	
strategies. However, the clinical development of dengue vaccines should not be forestalled by 326	
unnecessary regulatory concerns and information about the quality of vaccines on procedures 327	
for licensing can be found in various World Health Organisation documents (WHO, 2008). 328	
Although it was not a frequent finding among the studies reviewed, future studies should also 329	
account for serotype-specific immunity, herd protection, vector-host interactions, seasonal 330	
variations in disease transmission, age-specific differences in disease incidence and severity, 331	
potential effects of dengue vaccination on outbreak control spending, income from tourism 332	
and foreign direct investment flows. As also highlighted by Tozan (Tozan, 2016), only one 333	
study (Durham et al., 2013) modelled herd immunity to capture health gains by the 334	
community, including non-vaccinees; and despite Shepard (Shepard et al., 2004) considering 335	
its relevance to future economic analysis, they excluded potential indirect benefits of 336	
vaccination from their model due to the lack of evidence. Considering such aspects in 337	
economic models is more likely to assist in choosing the most efficient and cost-effective 338	
options for health interventions (Andraud et al., 2012). 339	
Generalisability was a neglected quality criterion. So while we identified that studies took 340	
similar methodological approaches to generating economic evidence for dengue fever 341	
vaccines, little attention was given to consider a vaccination strategy that could be adopted 342	
and adapted across the world.  343	
Recent studies have found that when investigators have financial relationships with 344	
pharmaceutical or product manufacturers, they are less likely to criticize the safety or 345	
efficacy of these agents and economic studies are more likely to report favorable qualitative 346	
assessments and less likely to report unfavorable qualitative assessments (Friedberg, 1999). 347	
Conflict of interest was declared non-existent among all selected studies and this statement is 348	
supported by the nonprofit nature of identified funding sources. 349	
Limitations 350	
The first dengue fever vaccine has been recently licensed in December 2015. Information 351	
about vaccine clinical effectiveness is still uncertain and it is not possible to have 352	
standardized economic parameters to compare studies on their findings and their overall 353	
quality. However, we attempted to minimize this limitation by using three recognized 354	
checklists for quality assessment. In spite of these limitations, results from this review are 355	
useful given the imminent licensure of other dengue fever vaccines and when further research 356	
about effectiveness is available. 357	
 358	
6. Conclusions 359	
Despite the growing consensus that dengue fever is one of the most important emerging 360	
tropical diseases in the 21st century (Gubler, 2002), few studies have provided economic 361	
evidence about dengue fever vaccines. What exists is of satisfactory overall quality and the 362	
increasing use of checklists to assess economic evaluations will likely improve overall 363	
quality of such studies. 364	
Although, several uncertainties still remain about effectiveness of dengue fever vaccines, 365	
preliminary cost-effectiveness studies performed so far favour the implementation of a 366	
dengue fever vaccine immunization programme. The price per dose is the most important 367	
factor affecting conclusions about the cost-effectiveness of future programmes. 368	
 369	
As dengue vaccines candidates have been approved for use in various countries it is 370	
extremely important to improve both the number and quality of studies in the area. Given the 371	
inherent complexity of economic analysis, it is important that future studies take on board the 372	
limitations of studies already performed to ensure the production of a reliable evidence base 373	
for decision-making.   374	
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APPENDIX 1 
 
Search Strategy 
 
1) Dengue [mp=title, abstract, subject headings, heading word, original title, 
keyword] 
2) Dengue/ or Dengue Hemorrhagic Fever/ or Dengue Shock Syndrome/ or Dengue 
virus /or dengue vaccine/ 
3) Aedes aegypti/ or Aedes/ or Aedes triseriatus/ or Aedes albopictus/ 
4) 1 or 2 or 3 
5) vaccine$ [mp=title, abstract, subject headings, heading word, original title, 
keyword] 
6) vaccination$ [mp=title, abstract, subject headings, heading word, original title, 
keyword] 
7) immunization [mp=title, abstract, subject headings, heading word, original title, 
keyword] 
8) 5or 6 or 7 
9) economic$ [mp=title, abstract, subject headings, heading word, original title, 
keyword] 
10) cost$ [mp=title, abstract, subject headings, heading word, original title, keyword] 
11) utilit$ [mp=title, abstract, subject headings, heading word, original title, keyword] 
12) QALY$ [mp=title, abstract, subject headings, heading word, original title, 
keyword] 
13) QUALY$ [mp=title, abstract, subject headings, heading word, original title, 
keyword] 
14) quality adjusted life year$ [mp=title, abstract, subject headings, heading word, 
original title, keyword] 
15) quality-adjusted life year$ [mp=title, abstract, subject headings, heading word, 
original title, keyword] 
16) quality-adjusted-life-year$[mp=title, abstract, subject headings, heading word, 
original title, keyword] 
17) DALY$ [mp=title, abstract, subject headings, heading word, original title, 
keyword] 
Appendix 1
18) disability adjusted life year$ [mp=title, abstract, subject headings, heading word, 
original title, keyword] 
19) disability-adjusted life year$ [mp=title, abstract, subject headings, heading word, 
original title, keyword] 
20) disability-adjusted-life-year$ [mp=title, abstract, subject headings, heading word, 
original title, keyword] 
21) hye$ [mp=title, abstract, subject headings, heading word, original title, keyword] 
22) health$ year equivalent [mp=title, abstract, subject headings, heading word, 
original title, keyword] 
23) hui$ [mp=title, abstract, subject headings, heading word, original title, keyword] 
24) life year$ gain$ [mp=title, abstract, subject headings, heading word, original title, 
keyword] 
25) life-year$ gain$ [mp=title, abstract, subject headings, heading word, original title, 
keyword] 
26) life year$ save$ [mp=title, abstract, subject headings, heading word, original title, 
keyword] 
27) life-year$ save$ [mp=title, abstract, subject headings, heading word, original title, 
keyword] 
28) preference weight$ [mp=title, abstract, subject headings, heading word, original 
title, keyword] 
29) resource$ adj3 use$ [mp=title, abstract, subject headings, heading word, original 
title, keyword] 
30) resource$ adj3 utili$ [mp=title, abstract, subject headings, heading word, original 
title, keyword] 
31) resource$ adj3 consum$ [mp=title, abstract, subject headings, heading word, 
original title, keyword] 
32) service$ adj3 use$ [mp=title, abstract, subject headings, heading word, original 
title, keyword] 
33) service$ adj3 utili$ service$ adj3 consum$ [mp=title, abstract, subject headings, 
heading word, original title, keyword] 
34) treatment$ adj3 use$ [mp=title, abstract, subject headings, heading word, original 
title, keyword] 
35) treatment$ adj3 utili$ [mp=title, abstract, subject headings, heading word, original 
title, keyword] 
36) treatment$ adj3 consum$ [mp=title, abstract, subject headings, heading word, 
original title, keyword] 
37) hospitali$ [mp=title, abstract, subject headings, heading word, original title, 
keyword] 
38) inpatient adj3 use$ [mp=title, abstract, subject headings, heading word, original 
title, keyword] 
39) inpatient adj3 utili$ [mp=title, abstract, subject headings, heading word, original 
title, keyword] 
40) inpatient adj3 consum$ [mp=title, abstract, subject headings, heading word, 
original title, keyword] 
41) in-patient adj3 use$ [mp=title, abstract, subject headings, heading word, original 
title, keyword] 
42) in-patient adj3 utili$ [mp=title, abstract, subject headings, heading word, original 
title, keyword] 
43) in-patient adj3 consum$ [mp=title, abstract, subject headings, heading word, 
original title, keyword] 
44) hospital adj3 use$ [mp=title, abstract, subject headings, heading word, original 
title, keyword] 
45) hospital adj3 utili$ [mp=title, abstract, subject headings, heading word, original 
title, keyword] 
46) hospital adj3 consum$ [mp=title, abstract, subject headings, heading word, 
original title, keyword] 
47) intervention$ adj3 use$ [mp=title, abstract, subject headings, heading word, 
original title, keyword] 
48) intervention$ adj3 utili$ [mp=title, abstract, subject headings, heading word, 
original title, keyword] 
49) intervention$ adj3 consum$ [mp=title, abstract, subject headings, heading word, 
original title, keyword] 
50) healthcare$ adj3 use$ [mp=title, abstract, subject headings, heading word, 
original title, keyword] 
51) healthcare$ adj3 utili$ [mp=title, abstract, subject headings, heading word, 
original title, keyword] 
52) healthcare$adj3consum$ [mp=title, abstract, subject headings, heading word, 
original title, keyword] 
53) health care$ adj3 use$ [mp=title, abstract, subject headings, heading word, 
original title, keyword] 
54) health care$ adj3 utili$ [mp=title, abstract, subject headings, heading word, 
original title, keyword] 
55) health care$ adj3 consum$ [mp=title, abstract, subject headings, heading word, 
original title, keyword] 
56) expenditure$ [mp=title, abstract, subject headings, heading word, original title, 
keyword] 
57) expense$ [mp=title, abstract, subject headings, heading word, original title, 
keyword] 
58) burden$ adj2 disease [mp=title, abstract, subject headings, heading word, original 
title, keyword] 
59) burden$ adj2 illness [mp=title, abstract, subject headings, heading word, original 
title, keyword] 
60) 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 
23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 
37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 
51 or 52 or 53 or 54 or 55 or 56 or 54 or 55 or 56 or 57 or 58 or 59 
61) 4 and 8 and 60 
 
APPENDIX 2 
 
DATABASE RESULTS KEYWORDS USED 
Embase 512 Dengue  MeSH or Dengue fever or Dengue 
hemorrhagic fever or dengue virus or Dengue Shock 
Syndrome or Aedes Aegypti 
 
And 
 
Vaccine  - MeSH or vaccination or immunization 
 
And  
 
economic$ - MeSH or cost$ - MeSH or economic$ or 
cost$ or utilit$ or QALY or QUALY or quality adjusted 
life year$ or quality-adjusted life year or quality-
adjusted-life-year$ or DALY$ or disability adjusted life 
year$ or disability-adjusted life year$ or disability-
adjusted-life-year$ or hye$ or health$ year equivalent or 
hui$ or life year$ gain$ or life-year$ gain$ or life year$ 
save$ or life-year$ save$ or preference weight$ or 
resource$ adj3 use$ or Resource$ adj3 utili$ or 
resource$ adj3 consum$ or Service$ adj3 use$ or 
service$ adj3 utili$ or service$ adj3 consum$ or 
treatment$ adj3 use$ or treatment$ adj3 utili$ or 
treatment$ adj3 consum$ or hospitali$ or inpatient adj3 
use$ or inpatient adj3 utili$ or inpatient adj3 consum$ or 
in-patient adj3 use$ or in-patient adj3 utili$ or  in-patient 
adj3 consum$ or hospital adj3 use$ or hospital adj3 
utili$ or hospital adj3 consum$ or  intervention$ adj3 
use$ or intervention$ adj3 utili$ or intervention$ adj3 
consum$ or  healthcare$ adj3 use$ or healthcare$ adj3 
utili$ or healthcare$adj3 consum$ or health care$ adj3 
use$ or health care$ adj3 utili$ or health care$ adj3 
consum$ or expenditure$ or expense$ or burden$ adj2 
disease or burden$ adj2 illness 
 
Global Health 196 
Medline 214 
Web of Science 115 
LILACS 57 
Dengue or Dengue fever or Dengue hemorrhagic fever 
or dengue virus or Dengue Shock Syndrome or Aedes 
Aegypti 
 
And 
 
Vaccine 
 
NHS EED 04 Dengue and Vaccine 
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Quality Assessment Checklist
Jefferson, 1996). 
	
QUESTIONS 
POSSIBLE ANSWERS 
Yes No Partially Non applicable 
St
ud
y 
D
es
ig
n 
1. Was the research question stated?     
2. Was the economic importance of the research 
question stated? 
    
3. Was/were the viewpoint(s) of the analysis clearly 
stated and justified? 
    
4. Was a rationale reported for the choice of the 
alternative programmes or interventions compared? 
    
5. Were the alternatives being compared clearly 
described? 
    
6. Was the form of economic evaluation stated?     
7. Was the choice of form of economic evaluation 
justified in relation to the questions addressed? 
    
D
at
a 
co
lle
ct
io
n 
8. Was/were the source(s) of effectiveness estimates 
used stated? 
    
9. Were details of the design and results of the 
effectiveness study given (if based on a single 
study)? 
    
10. Were details of the methods of synthesis or meta-
analysis of estimates given (if based on an overview 
of several effectiveness studies)? 
    
11. Were the primary outcome measure(s) for the 
economic evaluation clearly stated? 
    
12. Were the methods used to value health states and 
other benefits stated? 
    
13. Were the details of the subjects from whom 
valuations were obtained given? 
    
14. Were productivity changes (if included) reported 
separately? 
    
15. Was the relevance of productivity changes to the 
study question discussed? 
    
16. Were quantities of resources reported separately 
from their unit cost? 
    
17. Were the methods for the estimation of quantities 
and unit costs described? 
    
18. Were currency and price data recorded?     
19. Were details of price adjustments for inflation or 
currency conversion given? 
    
20. Were details of any model used given?     
21. Was there justification for the choice of model used 
and key parameters on which it was based? 
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n 
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 re
su
lts
 
22. Was time horizon of cost and benefits stated?     
23. Was the discount rate stated?     
24. Was the choice of rate justified?     
25. Was an explanation given if cost or benefits were 
not discounted? 
    
26. Were the details of statistical test(s) and confidence 
intervals given for stochastic data? 
    
27. Was the approach to sensitivity analysis described?     
28. Was the choice of variables for sensitivity analysis 
justified? 
    
29. Were the ranges over, which the parameters were 
varied, stated? 
    
30. Were relevant alternatives compared?     
31. Was an incremental analysis reported?     
32. Were major outcomes presented in a disaggregated 
as well as aggregated form? 
    
33. Was the answer to the study question given?     
34. Did conclusions follow from the data reported?     
35. Were conclusions accompanied by the appropriate 
caveats? 
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Quality Assessment Checklist
 
	
	
Co
st
s 
6. Has a summary of the expected resource use and unit costs for 
each alternative been provided, including a specification of the 
assumptions behind calculations of the costs? 
    
7. If productivity losses were estimated have they been reported 
separately? Has their relevance been discussed? 
    
8. Have the methods used to estimate them been described and 
justified? 
    
9. Is the currency stated? If so, is the date of the currency and 
prices used in the model stated with details of any conversions 
provided? 
    
E
ffe
ct
s 
10. Was the evidence identified systematically?     
11. Were the methods described? If a single study was used, was its 
internal validity discussed? If multiple studies were used, was 
the method used to synthesize the results also discussed? Was 
external validity of the evidence discussed? 
    
12. Was appropriate evidence of vaccine safety provided or 
referenced? 
    
13. If applicable, were the methods of valuation and source of the 
values described? 
    
14. Are adverse events from immunization impacts likely to have a 
substantial impact on the results of the analysis? If so, have they 
been included on both the costs and effects sides of the analysis? 
    
M
od
el
lin
g 
15. Are the model structure and implicit or explicit assumptions 
clearly described? 
    
16. Is the model type (static, dynamic or stochastic) clearly stated 
and justified in light of likely changes to the force of infection 
and the role of chance in the transmission process? Have the 
 
    
17. Has the model been validated? If so, has it been validated in as 
many facets of validation as possible? 
    
	
D
isc
ou
nt
in
g 
 
18. Is the discount rate clearly stated and justified? 
 
    
19. Has a sensitivity analysis been conducted to explore the impact 
of varying the discount rate? 
 
    
QUESTIONS 
POSSIBLE ANSWERS 
Yes No Partially Non applicable 
F
ra
m
in
g 
1. Is there a clear statement of the study question?     
2. Have the alternatives being compared been clearly stated?     
3. Has a cost-utility analysis been performed? If not, has that 
decision been justified appropriately? 
    
4. Is the perspective of the analysis clearly stated? If a societal or 
multiple perspectives have been adopted, have the costs and 
outcomes been disaggregated to allow judgments to be made 
from different perspectives? Are the costs and outcomes reported 
consistent with the perspective reported? 
    
5. Are the time frame and analytic horizon clearly stated and 
justified? 
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   20. Have the costs and effects been presented for all alternatives? 
    
21. Have dominated interventions been identified and excluded?     
22. Has sensitivity analysis been conducted to assess the robustness 
of the findings to changes in the value of key parameters? Has 
the choice of parameters and the ranges over which they have 
been subjected to sensitivity analysis been stated and justified? 
    
23. Has the national CE threshold been used, if one exists? If there 
is no national CE threshold, have the results of the evaluation 
been classified according to the per capita national GDP of the 
country in question? 
    
24. Have the findings been compared to other economic evaluations 
undertaken in the same or neighbouring countries? 
    
O
th
er
 
fa
ct
or
s 
25. Is there a discussion of other important factors in the decision 
under consideration? 
    
Co
nc
lu
sio
ns
 26. Is an answer given to the study question? 
 
    
27. Do the conclusions follow from the data reported? 
 
    
28. Are the conclusions accompanied by the appropriate caveats? 
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Quality Assessment Checklist D. Constenla et al. C  (Constenla et al., 
2015). 
 
	
QUESTIONS 
POSSIBLE ANSWERS 
Yes No Partially Non applicable 
St
ud
y 
D
es
ig
n 
1 a. Was the research question stated and justified?     
b. Was the patient population defined?     
c. Was the rationale for choosing the patient population 
explained?     
d. Was the viewpoint of the analysis clearly stated and 
justified?     
2 a. Was the choice of comparator explained? (applicable 
only if CMA, CEA, CBA)     
b. Was the reason for choosing the comparator stated? 
(applicable only if CMA, CEA, CBA)     
3 a. Was a recognized type of economic analysis used? (e.g. 
CA, CMA, CEA, CBA, COI)     
b. Are the methods used in the study described and 
justified?     
c. Was a decision tree/model included as a figure? 
(applicable only if a CEA)      
4 a. Were the primary outcome measures for the study 
described?      
b) Was the rationale for choosing these measures 
explained?      
D
at
a 
Co
lle
ct
io
n 
5 a. Was the choice of data capture explained and justified?     
b. Were any limitations of the data explained?      
6 a. Was the source of probability of clinical events given? 
(applicable only if CMA, CEA, CBA, COI)      
b. Are outcome data collected at same as resource use data? 
(along side RCT)      
c. Were methods to value health states or other benefits 
explained? (if DALYs, QALYs were used)      
7 a. Were currency and price adjustments for inflation or 
currency conversion 
explained?  
    
8 a. Was discounting clearly reported and justified?      
b. Was the time span of data collection of all relevant costs 
described?     
9 a. Were all relevant costs (direct/indirect) identified and 
sources of these given?      
b. Were methods for the estimation of all relevant costs 
described?      
c. Were indirect costs measured and reported separately 
from the direct costs?     
d. Were all relevant costs recent? (2-3 years from when the 
study was published)      
10 a. Have all assumptions been specified and listed?      
b. Were details of any model used reported and justified?      
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11 a. Were statistical tests and confidence intervals used and 
justified?     
b. Were the base results both statistically and clinically 
significant?     
12 a. Were adequate sensitivity analyses conducted and the 
choice of variables justified?      
b. Did the sensitivity analyses include all reasonable 
scenarios that might affect the study results?     
13 Are potential sources of bias presented?      
14 Were incremental analyses reported?      
15 Were appropriate comparisons made with other studies?      
16 a. Does the evidence concur with the conclusions of the 
study?      
b. Does the evidence answer the research question?      
17 a. Are the conclusions justified?      
b. Can the conclusions be generalized?      
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